Summary
The AI response claims anemia/hypoxia and related monitoring/counseling, but the supplied FDA label excerpts provided only address embryo-fetal toxicity, contraception, and pregnancy-related counseling. Those specific safety/monitoring claims are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Welireg (belzutifan) can cause anemia (low red blood cell count).
Not supported by the supplied label excerpts (only embryo-fetal toxicity and reproductive risk/contraception are provided).
Welireg (belzutifan) can cause hypoxia (low blood oxygen levels).
Not supported by the supplied label excerpts.
Welireg (belzutifan) can cause fatigue.
Not supported by the supplied label excerpts.
Welireg (belzutifan) can cause dizziness.
Not supported by the supplied label excerpts.
Welireg (belzutifan) can cause nausea.
Not supported by the supplied label excerpts.
Welireg (belzutifan) can cause shortness of breath.
Not supported by the supplied label excerpts.
The anemia and hypoxia effects are among the clinically important risks.
Not supported by the supplied label excerpts.
Anemia and hypoxia effects can occur in patients receiving Welireg for cancer-related uses.
Not supported by the supplied label excerpts; no indication-specific safety information for anemia/hypoxia is included.
Monitoring is used to detect worsening blood counts and oxygenation early in patients receiving Welireg.
Not supported by the supplied label excerpts.
Patients receiving Welireg are advised to seek medical attention if they develop symptoms that can signal worsening anemia or low oxygen, such as increasing shortness of breath, unusual tiredness or weakness, and dizziness.
Not supported by the supplied label excerpts.
Contradictions
Important Omissions
Embryo-fetal toxicity content from the provided label excerpts (e.g., WELIREG can cause fetal harm; animal study findings; advise pregnant women/females of reproductive potential of fetal risk; contraception counseling including effective non-hormonal contraception and timing after last dose; verify pregnancy status).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple adverse effect and monitoring/counseling claims that are not supported by the provided prescribing information excerpts. This creates risk of relying on unverified safety statements rather than label-supported counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (anemia/hypoxia and related symptoms/monitoring) are not supported by the supplied FDA label sections, which concern embryo-fetal toxicity and reproductive counseling.
Suggested Improvement
Limit claims to the provided label content (embryo-fetal toxicity, pregnancy risk, and contraception/pregnancy verification instructions). If additional safety/monitoring statements are intended (e.g., anemia/hypoxia), include the corresponding FDA label sections (Warnings/Precautions, Adverse Reactions, Counseling/Monitoring) as evidence.